NAD+ injections

Oral vs subcutaneous vs IV, at a glance

The short version: oral NAD+ does not work, subcutaneous is the cheap self-administered route, and IV is the fastest and most studied but the most expensive. None of the three has an outcomes trial behind the marketed benefits.

What NAD+ is, in one paragraph

NAD+ (nicotinamide adenine dinucleotide) is a coenzyme every cell uses to turn food into energy and to run repair and longevity pathways, including the sirtuin enzymes. Levels fall with age, which is the whole pitch behind NAD+ drips and shots. Because the intact molecule is not absorbed by mouth, people inject it - subcutaneously or intravenously - rather than swallow it. For the full compound record, redox chemistry, and half-life caveats, see the NAD+ library reference.

Doses people use

The study-flagged row carries a source you can open. Everything marked community is clinic and community practice - what people do, not what a trial established, and not a recommendation. There is no proven effective dose because no dose-response trial exists.

Note the units: subcutaneous NAD+ is often dosed in millilitres of a made-up solution rather than in milligrams, because it is a compounded product with no manufacturer standard. That is why the reconstitution math matters - work out the mg-per-mL of your own vial in the reconstitution calculator.

Titrating the flush

NAD+ given quickly is notorious for a cluster of symptoms people call the flush: chest tightness or pressure, a wave of warmth, nausea, and abdominal cramping. In the IV tolerability pilot these infusion-related symptoms were common, and they are why clinics slow the drip right down - the discomfort tracks how fast the NAD+ goes in, not just how much.

The practical pattern people follow is start low and go slow: a small starting volume, given slowly, then increasing over sessions as tolerance builds. On an IV that means a longer, slower infusion; with a subcutaneous shot it means a smaller volume per injection and more frequent, smaller doses rather than one large one. This is tolerance management, not an efficacy claim - ramping up does not make an unproven therapy work, it only makes the flush easier to sit through. Anyone with a heart condition should treat the chest-tightness reaction as a reason to involve a licensed provider, not to push through.

Storage and stability after reconstitution

This is the question people search for most and find answered worst, because injectable NAD+ is a compounded product and vendors do not agree. Here is what the guidance actually says, and where it is soft.

Side effects and the product-safety risk

Two different kinds of risk sit under NAD+ injections. The first is the dose-rate flush already described - chest tightness, warmth, nausea, and cramping when it goes in too fast - plus ordinary injection-site reactions for subcutaneous shots.

The second is the bigger one, and it is about the product rather than the molecule. Injectable NAD+ is not FDA-approved and is made by compounding pharmacies, so sterility and purity are not centrally guaranteed. The FDA issued a Class I recall - its most serious tier - for a compounded NAD+ injectable after a vial tested far above the safe endotoxin limit and three patients required emergency care. There is no established list of drug interactions for injected NAD+ because the human data is too thin to have produced one, which is a reason for caution, not reassurance.

What the evidence supports vs the IV-bar pitch

The clinic marketing sells outcomes: more energy, slower aging, easier addiction recovery. The human evidence supports none of those for injected NAD+. It supports a narrower set of facts - that NAD+ is a real and essential coenzyme, that a 6-hour IV infusion produces measurable but complex blood kinetics, and that small pilots found the infusions broadly tolerable when given slowly. That is target engagement and tolerability, not proof of benefit.

The strongest-looking evidence you will see quoted is usually about the precursors NR and NMN, which do raise blood NAD+ in humans - but that is a different molecule taken a different way, and a competitor page was even found misciting a precursor trial as if it were a subcutaneous-NAD+ study. Treat any specific benefit, half-life, or interaction figure you see for NAD+ injections as unverified until a real trial exists.

Questions people ask

Sources

1. [1]Amjad S, et al. Role of NAD+ in regulating cellular and metabolic signaling pathways. Mol Metab. 2021 (PMC7973386) PMID 33609766reviewNAD+ as a core coenzyme in redox reactions and as the required cosubstrate for sirtuins and PARP1, which consume it.
2. [2]Grant R, et al. Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour IV Infusion of NAD+. Front Aging Neurosci. 2019 (PMC6751327)studyThe only located human IV-NAD+ pharmacokinetic study (750 mg over 6 hours, n=8); delayed, non-standard kinetics with no half-life derived.
3. [3]Gallagher C, Emmanuel OO. NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Res Rev. 2026 PMID 41655607reviewA 2026 systematic review of 113 studies: no outcomes trials evaluated intravenous or intramuscular NAD+ itself for anti-aging or wellness; oral NR and NMN show biochemical target engagement but heterogeneous, often null functional results.
4. [4]Reyna et al. IV NAD+ versus NR: a retrospective tolerability pilot in a real-world setting. Front Aging. 2026 (PMC12907335)study500 mg IV real-world tolerability data and the explicit statement that no trials have compared clinical outcomes between NAD+ and its precursors.
5. [5]NAD+ and Enkephalinase Inhibition Infusions in Substance Use Disorder in Fifty Cases. Curr Psychiatry Res Rev. 2022studyThe addiction-recovery NAD+ evidence base is a single uncontrolled 50-case pilot series whose own authors call for randomized controlled follow-up.
6. [6]Nkrumah-Elie Y, et al. Preliminary Safety Analysis of Injections of Nicotinamide Riboside Chloride. medRxiv preprint. 2026studyOne of the only located human trials dosing NAD+ itself via SubQ/IM/IV (100 mg for 3 days, 4-6 subjects per arm); tolerability only, not peer-reviewed.
7. [7]Song J, et al. The Safety and Antiaging Effects of NMN in Human Clinical Trials: an Update. Adv Nutr. 2023 (PMC10721522)reviewNAD+ itself cannot be absorbed orally or cross the cell membrane intact; catalogs the human NMN precursor trials that do exist - kept separate from NAD+ injection claims.
8. [8]Conze D, Brenner C, Kruger CL. Safety and Metabolism of Long-term NIAGEN (Nicotinamide Riboside Chloride). Sci Rep. 2019 (PMC6611812)studyPrecursor context: an NR randomized trial (n=140) raised whole-blood NAD+ by 22, 51, and 142% at 100, 300, and 1000 mg. This is NR, not NAD+ injection.
9. [9]Okabe K, et al. Oral NMN Is Safe and Efficiently Increases Blood NAD+ Levels in Healthy Subjects. Front Nutr. 2022 (PMC9036060)studyPrecursor context: an NMN trial raising blood NAD+, kept clearly separate from NAD+ injection claims.
10. [10]Empower Pharmacy - NAD+ Injection (compounding pharmacy product page)communityStorage and reconstitution practice, and the explicit disclosure that NAD+ injection is not FDA-approved and is 503A-compounded only.
11. [11]BBB National Programs, National Advertising Division decision re: Reus Research (Cata-Kor NAD+), 2025regulatoryAn independent advertising review finding no human clinical studies on oral or liposomal NAD+ ingestion raising NAD+ levels.
12. [12]FDA Issues Class I Recall for NAD+ Injection Due to Elevated Endotoxin Levels (news, citing FDA enforcement report)regulatoryA real compounded-NAD+ safety incident: a Class I recall for endotoxin contamination after three patients required emergency care.
13. [13]NAD IV Therapy Cost - pricing by dosage, clinic vs mobile (California Infusion Centers)pricingIn-clinic NAD+ IV pricing of roughly $429-$879 per session by dose, and NAD+ injections quoted at $60-$289. Clinic pricing page, accessed 2026-08-24.
14. [14]Cost of NAD IV Therapy - pricing, packages, and what to expect (Omre)pricingNAD+ IV commonly $300-$800 per session (range ~$250-$2,000+), with injections at $40-$200 each - corroborating the subq-is-cheaper comparison. Clinic pricing page, accessed 2026-08-24.